The most important Alzheimer's research of 2025 just dropped, and it completely reframes what it means to carry APOE4.

I just published a deep-dive video on findings from the AD/PD International Conference that every APOE4 carrier needs to see:

The Headline: APOE4 carriers respond BETTER to structured lifestyle interventions than non-carriers.

The Evidence:

• 150% greater improvement in processing speed (vs 60% in non-carriers)

• 83% better executive function outcomes

• 60% reduction in multi-morbidity

• Sustained benefits 11 years after intervention

The Mechanism: The same pathways that make APOE4 carriers vulnerable (lipid metabolism, glucose regulation, inflammation) are the exact ones that respond most dramatically to intervention.

The Urgency: Biomarker data (p-tau217) shows early intervention is critical. Wait too long, and the window narrows significantly.

The Protocol: The FINGER trial's five-domain approach isn't revolutionary in its components - it's revolutionary in its systematic application and proven outcomes.

What This Means: If you carry APOE4, you're not less treatable - you're potentially MORE responsive to the right interventions.

But timing matters. Those who start with lower p-tau217 levels see dramatically better results.
The FINGER protocol isn't complex - it's systematic:

• Mediterranean-style nutrition

• Zone 2 cardio + strength training

• Cognitive engagement

• Social connection

• Vascular risk management

Watch the full breakdown here:

We're implementing these protocols in The Phoenix Community with personalized protocols, tracking, and peer support. This is the best way to beat the odds!

But whether you join us or not, please watch this video.
The data could change everything about how you approach your APOE4 status.

Cheers,
Kevin

Sources:

Expert in the video: Dr. Miia Kivipelto - Professor of Clinical Geriatrics at Karolinska Institutet, Center for Alzheimer Research, and senior geriatrician and Director for Research & Development of Medical Unit Aging at Karolinska University Hospital in Stockholm, Sweden.

ADPD Conference topic: PIVOTAL POINTS IN PREVENTION TRIALS AND THE NEW ERA OF PRECISION MEDICINE FOR ALZHEIMER’S DISEASE AND RELATED DISORDERS